The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Johnson & Johnson announced Aug. 20 it entered into a definitive agreement to acquire V-Wave Ltd., a privately held company that develops treatment options for heart failure. Under the terms of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CAESAREA, Israel, April 26, 2018 /PRNewswire/ -- V-Wave Ltd., an Israel-based company that has developed a proprietary, minimally invasive implanted interatrial shunt device for treating patients with ...

CAESAREA, Israel--(BUSINESS WIRE)--V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF), announced today the results of its first human ...

Johnson & Johnson announced the acquisition of heart disease medical device maker V-Wave in a deal worth up to $1.7 billion. Announced Tuesday, the transaction involves J&J paying $600 million upfront ...

Global healthcare giant Johnson & Johnson (J&J) announced on Tuesday that it will acquire Israeli startup V-Wave for up to $1.7 billion, in a strategic move by J&J to bolster its position in the ...

Johnson & Johnson (J&J) has announced that it will be acquiring medical device company V-Wave in a deal worth up to $1.7bn. The agreement will give J&J’s medtech division access to a cardiovascular ...

US-based pharmaceutical company Johnson & Johnson said Tuesday that it will acquire V-Wave, a medical device company focusing on patients with heart failure, for up to $1.7 billion. The agreement ...

Johnson & Johnson aims to add a fourth cardiac business to its portfolio in less than two years with the acquisition of V-Wave Ltd., which makes the Ventura interatrial shunt system for the treatment ...

A novel percutaneously implanted unidirectional shunt for the treatment of systolic HF showed promising safety and efficacy outcomes at 3 months, according to new findings presented at TCT 2015. The ...